Cook MyoSite is at the forefront of regenerative medicine, specializing in personalized investigational cell therapy products that utilize the patient's own muscle cells. This innovative approach begins and ends with the patient's body, ensuring a tailored treatment experience. Currently, these therapies are under investigation in clinical trials and are not yet commercially available, highlighting the company's commitment to advancing the field of cellular therapies through rigorous research and development.

The company is also involved in various scientific studies that explore the mechanisms of muscle regeneration and the role of different cellular components in this process. Research efforts include advancements in gene editing techniques, such as CRISPR/Cas9, to enhance the efficiency of modifying primary human myoblasts. Additionally, Cook MyoSite is engaged in developing novel bioprinting platforms for engineering muscle and tendon tissues, as well as investigating the effects of various factors on muscle homeostasis and regeneration. These technologies collectively aim to improve therapeutic outcomes for patients suffering from muscle-related conditions.

United States

Cook MyoSite is on a mission to make regenerative medicine a part of everyday medicine. As an industry leader in muscle cell technology, we’re establishing new paradigms for muscle-related disorders. Established in 2002, Cook MyoSite was created to guide the Cook Group organization into the expanding world of cellular technologies. We’re proud to be a part of the vibrant medical community in Pittsburgh, Pennsylvania.

Cook MyoSite

Company Details